CONMED Corporation

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 8, 2025, the Board of Directors (the “Board”) of CONMED Corporation (the “Company”) appointed Kim Kelderman as a director effective immediately. Mr. Kelderman was appointed to the Corporate Governance and Nominating Committee and the Strategy Committee. The Board determined that Mr. Kelderman is independent and meets the applicable director independence requirements of the New York Stock Exchange and the Company’s director independence standards, as adopted by the Board. Mr. Kelderman has been President, Chief Executive Officer, and member of the Board of Bio-Techne (NASDAQ: TECH) since February 2024, having joined Bio-Techne in April 2018, as President, Diagnostics and Genomics, and having served as Chief Operating Officer from November 2023 to January 2024. Prior to Bio-Techne, Mr. Kelderman was employed at Thermo Fisher Scientific where he led three different businesses of increasing scale and complexity. Mr. Kelderman managed the Platforms and Content of the Genetic Sciences Division, where he was responsible for the Instrumentation, Software, Consumables and Assays businesses, and brands such as Applied Biosystems and legacy Affymetrix. Before joining Thermo Fisher, Mr. Kelderman served as Senior Segment Leader at Becton Dickinson, managing the global Blood Tubes "Vacutainer" business. Mr. Kelderman holds a Bachelor of Science degree from Hogeschool Heerlen of Applied Sciences in the Netherlands. There are no understandings or arrangements between Mr. Kelderman or any third parties pursuant to which he was selected as a director. There are no related party transactions that would be required to be disclosed under Item 404(a) of Reg S-K with respect to Mr. Kelderman. In addition, Mr. Kelderman does not have any familial relationship with any director or executive officer of the Company. As a non-employee director, Mr. Kelderman will receive the annual cash and equity compensation received by each of the Company’s non-employee directors, as further described in the Company’s proxy statement dated April 8, 2025. The Board granted Mr. Kelderman a prorated portion of the annual equity compensation granted to directors with a value of approximately $134,766, based on a Black Scholes valuation, which grant was comprised of 500 restricted stock units and stock options to acquire 6,227 shares of the Company’s common stock with an exercise price equal to the closing price of the Company’s stock on September 8, 2025. The awards will vest in full on September 8, 2026. A copy of a press release issued on September 9, 2025, announcing Mr. Kelderman’s election and describing his background and qualifications is attached to this Current Report on Form 8-K as Exhibit 99.1.